Alerts will be sent to your verified email
Verify EmailONESOURCE
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
OneSource Specialty Pharma is India’s first specialty pharma pure-play Contract Development and Manufacturing Organization (CDMO). With comprehensive experience in the development and manufacturing of specialized drug-device combinations, the company can provide consistent support and quality throughout the full life cycle of complex combination product.
Onesource Specialty major competitors are Natco Pharma, Pfizer, Astrazeneca Pharma I, Granules India, Eris Lifesciences, Caplin Point Lab, Alembic Pharma.
Market Cap of Onesource Specialty is ₹20,655 Crs.
While the median market cap of its peers are ₹18,861 Crs.
Onesource Specialty seems to be less financially stable compared to its competitors.
Altman Z score of Onesource Specialty is 8.77 and is ranked 5 out of its 8 competitors.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Jan May | Mar May Jun Aug Nov | |||||||||||||||||
| Investor Presentation | Jan May | Aug Sep Nov | |||||||||||||||||
| Conference Call | Jan May | Mar Jun Nov | |||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Claude
|
